Search Results

What Black Women Need to Know About Breast Cancer Risk A healthcare provider holding a tablet speaks with a patient seated on an exam table in a medical office Breast cancer is the most commonly diagnosed cancer in Black women. And while Black women have an overall lower breast cancer incidence rate than white women,…

Jody has worked as a nurse practitioner in breast surgical oncology with Maryland Oncology since 2021. She graduated with her Associates of Science degree in nursing in 2006 followed by her BSN in 2008. She completed her undergraduate studies in Pennsylvania and her Masters of Science degree in nursing at George Washington University. The majority…

A PHASE III RANDOMIZED, OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT, BOTH COMBINED WITH A CDK4/6 INHIBITOR, IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657) MOA: Giredestrant is an oral selective estrogen receptor degrader (SERD) Key Eligibility Criteria: Locally advanced or metastatic…

Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001) MOA: Rinatabart sesutecan (Rina-S) is an FRα-directed antibody drug conjugate with an exatecan payload. Key Eligibility Criteria: Cohort B3 – EGFR-mutated NSCLC Must have received EGFR-targeted therapy and plt-based chemo Part C – High-grade serous PROC 1-3 prior lines…

A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression >= 50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression (J3M-MC-JZQB) MOA: LY3537982 is…

Maryland Oncology’s Laurel location is located adjacent from the former Laurel Regional Hospital. MOH’s Laurel location was founded in 2011 with only one provider 2 days a week. MOH’s Laurel location is open 2 ½ days a week with 2 Oncologist serving the Oncology Hematology patients in the area.